A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Nov 2017
At a glance
- Drugs IMO 8400 (Primary)
- Indications Dermatomyositis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Idera Pharmaceuticals
- 06 Nov 2017 According to an Idera Pharmaceuticals Inc. media release, clinical data results from this trial are expected in the second quarter of 2018.
- 10 Oct 2017 Planned End Date changed from 1 Aug 2017 to 1 Sep 2018.
- 10 Oct 2017 Planned primary completion date changed from 1 Aug 2017 to 16 May 2018.